FINWIRES · TerminalLIVE
FINWIRES

Godrej Properties Awards INR11 Billion Contract to Tata Projects for Gurgaon Luxury Trio

By

Real estate developer Godrej Properties (NSE:GODREJPROP, BOM:533150) has partnered with engineering and construction company Tata Projects for three of its luxury developments in Gurgaon, India, according to a Friday filing to the Indian stock exchanges.

Under the pact, Tata Projects has awarded a contract worth 11 billion Indian rupees. The order is for setting up the core and shell construction works across Godrej Properties' three upcoming projects, Godrej Sora, Godrej Astra, and Godrej Samaris in Gurgaon.

The company said this is its largest single construction contract award to date.

Godrej Properties' shares were up nearly 1% in recent trade.

Related Articles

Asia

Shengnuo Biotec's Unit Completes Drug Master File Registration for Terlipressin Acetate With US FDA

Chengdu Shengnuo Biotec's (SHA:688117) unit, Chengdu Shengnuo Biopharmaceutical, completed the drug master file registration with the U.S. Food and Drug Administration for the active pharmaceutical ingredient, terlipressin acetate, according to a Shanghai bourse filing on Friday.The drug is used for treating bleeding in the gastrointestinal and genitourinary systems.The peptide drugmaker's shares rose by less than 3% at the close.

$SHA:688117
Asia

Electrification in China's Heavy-Duty Truck Sector to Increase Competition, S&P Says

Electrification among China's heavy-duty trucks could pick up, which would heighten competition in the sector, S&P Global Ratings said in a recent release.Anchoring government policies, technological innovation, and reduced ownership costs will help accelerate electrification in the industry, S&P said.Increased competition could test traditional producers' capacity to shield their market share, the rating agency said.S&P also expects local heavy-duty truck sales volume to weaken in 2026, after strong demand in 2025 due to policy incentives.As a result, the rating agency projects the market to be mainly replacement-driven within the next few years.Manufacturers will increase their overseas expansion amid strong demand in emerging markets, offsetting the domestic slowdown, S&P said.

$^SSEC$^SZSE
Asia

Zhejiang Orient Gene Biotech Gets International, Domestic Medical Device Certificates

Zhejiang Orient Gene Biotech (SHA:688298), along with two of its subsidiaries, obtained a number of international and domestic medical device registration certificates for their devices, according to a Friday disclosure on the Shanghai bourse.The domestic certificates were handed to three devices, which are test kits for hepatitis C virus, helicobacter pylori and bordetella pertussis nucleic acid.The international certificates were handed down to six devices, while U.S. Clinical Laboratory Improvement Amendments certificates were handed down to two test kits under the Healgen brand.

$SHA:688298